Publication
Paving the way for combination therapies
In November 2023, the UK Competition & Markets Authority (CMA) released its Prioritisation statement on combination ther...
Publication
In November 2023, the UK Competition & Markets Authority (CMA) released its Prioritisation statement on combination ther...
Publication
Welcome to our WHS Law Briefing. This briefing identifies key issues and emerging trends in WHS law, and details the sig...
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the adm...
Publication
In November 2023, the UK Competition & Markets Authority (CMA) released its Prioritisation statement on combination ther...
Publication
Welcome to our WHS Law Briefing. This briefing identifies key issues and emerging trends in WHS law, and details the sig...
© Norton Rose Fulbright LLP 2023